A first New Zealand study looked at the role of lutetium-177-P SMA I &T in the progression of metastatic castrate-resistant prostate cancer
Vyas, Madhusudan; Garett, N.; Lim, R.; Fagan, J.
View fulltext online
Citation:Vyas, M., Garett, N., Lim, R., & Fagan, J. (2021, November). A first New Zealand study looked at the role of lutetium-177-P SMA I &T in the progression of metastatic castrate-resistant prostate cancer. Paper presented at the National ITP Research Symposium 2021, Wellington, New Zealand.
Permanent link to Research Bank record:https://hdl.handle.net/10652/5590
Prostate cancer that has spread beyond the prostate gland and is resistant to castration is a deadly disease that poses a threat to men's health. The current standard of care for metastatic prostate cancer is hormonal manipulation. However, metastatic castration-resistant prostate cancer (mCRPC) remains a significant treatment and management challenge. Recently, the use of lutetium-177 (Lu177) labelled ligands against PSMA was found to be compelling and resulted in an increase in overall patient survival.